National Institute of Technology Rourkela (NIT Rourkela) Researchers have investigated a novel semiconductor device-based biosensor that can identify breast cancer cells without requiring complicated or expensive laboratory procedures.
Led by Prof. Prasanna Kumar Sahu, Department of Electrical Engineering, along with his research scholar Dr. Priyanka Karmakar, the findings of this research have been published in the prestigious Microsystem Technologies journal.
In recent years, the rise of potentially fatal illnesses has drawn attention to the global emphasis on biomolecule evaluation and Point-of-Care (POC) testing. Among these diseases, cancer is a significant global public health concern. In this context, India has seen a substantial rise in breast cancer cases in the past few decades.
Since cancer cells often do not show any initial signs of progression, it is crucial to diagnose them at an early stage for prevention and cure. While several diagnostic procedures, such as X-ray, mammography, Enzyme-Linked Immunosorbent Assay Test (ELISA), Ultrasonography, and Magnetic Resonance Imaging (MRI), are used to identify the disease, they require specialised equipment and trained personnel. Additionally, these diagnostic methods are often inaccessible to people in remote areas.
To take advantage of this, the research team has proposed an electronic device, ‘TFET’ (Tunnel Field Effect Transistor), based on TCAD simulation results, to detect breast cancer cells effectively. FETs are commonly used in electronics, but they have been adapted to function as a sensitive detector of biological materials. Unlike many traditional tests, this biosensor requires no added chemicals or labels to work.
The findings show that the sensor is sensitive in detecting T47D cancer cells due to their high density and permittivity. It is also highly effective at distinguishing the cancerous cells from healthy breast cells, offering improved sensitivity compared to existing technologies.
Another key feature of the developed technology is its affordability. A TFET-based biosensor is affordable compared to the conventional testing methods and other existing FET-based biosensors. The developed technology holds significant promise for future medical applications, resulting in low-cost, easy-to-use diagnostic devices that bring early breast cancer detection to clinics, mobile testing units, and home settings.
As the next step, the research team explores potential collaborations for fabrication and scientific validation of the developed technology.
